Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Argo Biopharma

Request full access

Next-generation siRNA therapeutics for chronic diseases

ChinaFounded 2021Biotech & Life Sciences

About Argo Biopharma

Shanghai Bowang Pharmaceutical, operating as Argo Biopharma, is a clinical-stage biotechnology company founded in April 2021. The company was established by co-founders Dr. Dongxu Shu, the CEO, and Dr. Patrick Shao, the CSO, along with Shiwei Xia. Dr. Shu previously served as a senior scientist at Arrowhead Pharmaceuticals, focusing on extrahepatic delivery platforms, and holds a Ph.D. in chemistry from the University of Wisconsin-Madison. Dr. Shao has over two decades of experience in drug research, including roles at Mitotherapeutix and as Director of Medicinal Chemistry at Arrowhead Pharmaceuticals.

Argo Biopharma specializes in the discovery and development of next-generation small interfering RNA (siRNA) therapeutics. The firm's business model is centered on its proprietary RNAi platform technology, known as RADS (RNA molecules with superior Activity, Durability, and Safety). This platform is the foundation for a pipeline of drug candidates aimed at treating a wide range of indications, including cardiovascular and metabolic diseases, rare diseases, central nervous system (CNS) disorders, viral hepatitis, and complement-mediated diseases. The company's goal is to create transformative medicines for chronic disease management, with some drug candidates holding the potential for a single annual injection for certain indications.

The company operates in the global biopharmaceutical market and generates revenue through strategic partnerships, collaborations, and licensing agreements. A significant milestone was a strategic collaboration with Novartis in January 2024, involving substantial upfront payments and potential total value exceeding $4 billion. Since its inception, Argo has secured significant funding, including a nearly $5 million angel round in May 2021, a $63 million Series A round in March 2022, and a Series A+ round of over $40 million in November 2023. As of mid-2025, the company has multiple siRNA candidates in clinical development, with its first Investigational New Drug (IND) application approved in December 2022.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2021
Headquarters
China
Employees
34
Open positions
None listed
Dealroom signal
54.8/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Nov 2023 $41M $413M Trinity Innovation Fund · Tao Capital · Huagai Capital · SDIC Fund Management ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Argo Biopharma website traffic

Latest recorded traffic for Argo Biopharma is 1.7K monthly website visits, down 15% over the last three months. Argo Biopharma's team grew 580% over the past year.

Latest monthly visits1.7K 3-month web change-15% 1-year team growth+580%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Argo Biopharma in its local ecosystem

Live from Dealroom

The Argo Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Trinity Innovation Fund
  • Tao Capital
  • Huagai Capital
  • SDIC Fund Management
  • GSR United Capital
Employees 34 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇳 China57.7%
🇺🇸 United States38.5%
🇩🇪 Germany3.9%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Argo Biopharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Argo Biopharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.